Telomir Pharmaceuticals, Inc. 8-K — AI Bull & Bear Analysis

Telomir Pharmaceuticals' 8-K filing marks a pivotal shift in its administrative strategy as it moves from a traditional executive structure to a consulting-based financial model. While the company emphasizes that the departure of the previous CFO was amicable and not due to disagreements, the timing and nature of the replacement suggest a tightening of the corporate belt. Investors are left to weigh the benefit of professionalized, low-cost financial oversight against the risks associated with a lack of dedicated, full-time financial leadership in a capital-intensive industry.